Morgan Stanley lowered the firm’s price target on Nurix Therapeutics to $9 from $12 and keeps an Equal Weight rating on the shares after earnings and the company having announced on November 1 that FDA has placed a partial clinical hold on the Phase 1 study evaluating BTK degrader NX-2127 in various B-cell malignancies. The firm’s lower price target assumes about $1.1B in risk-adjusted revenue in 2035, the analyst noted.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NRIX:
- Nurix Therapeutics Announces Presentations at the 65th American Society of Hematology (ASH) Annual Meeting
- FDA puts partial clinical hold on Nurix’s Phase 1 NX-2127-001 study
- Nurix Therapeutics Announces Partial Clinical Hold For NX-2127 Phase 1 Trial
- Cathie Wood’s ARK Investment bought 140K shares of Nurix Therapeutics today
- Nurix Therapeutics price target lowered to $24 from $31 at Baird
